Literature DB >> 28159875

What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise.

Dennis R Burton1.   

Abstract

Functional antibodies, i.e., those with antipathogen activity in in vitro assays, are generally the best correlate of vaccine protection. Mimics of natural infection, including live attenuated and killed pathogens, which induce such antibodies in vivo, have generated highly successful vaccines. However, pathogens that induce functional antibodies at lower levels or more sporadically have been more refractory to vaccine design. Such pathogens are being tackled by more systematic approaches involving identifying functional antibodies, templating immunogens from the antibodies, and then evaluating the immunogens iteratively. I believe this is a powerful new approach to vaccine design as discussed below.
Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28159875      PMCID: PMC5540812          DOI: 10.1101/cshperspect.a030262

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  30 in total

Review 1.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

2.  A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

Authors:  Devin Sok; Matthias Pauthner; Bryan Briney; Jeong Hyun Lee; Karen L Saye-Francisco; Jessica Hsueh; Alejandra Ramos; Khoa M Le; Meaghan Jones; Joseph G Jardine; Raiza Bastidas; Anita Sarkar; Chi-Hui Liang; Sachin S Shivatare; Chung-Yi Wu; William R Schief; Chi-Huey Wong; Ian A Wilson; Andrew B Ward; Jiang Zhu; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

3.  Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B-cell responses after boosting.

Authors:  Christopher Sundling; Paola Martinez; Martina Soldemo; Mats Spångberg; Karin Lövgren Bengtsson; Linda Stertman; Mattias N E Forsell; Gunilla B Karlsson Hedestam
Journal:  J Infect Dis       Date:  2012-11-16       Impact factor: 5.226

4.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.

Authors:  Davide Corti; Siro Bianchi; Fabrizia Vanzetta; Andrea Minola; Laurent Perez; Gloria Agatic; Barbara Guarino; Chiara Silacci; Jessica Marcandalli; Benjamin J Marsland; Antonio Piralla; Elena Percivalle; Federica Sallusto; Fausto Baldanti; Antonio Lanzavecchia
Journal:  Nature       Date:  2013-08-18       Impact factor: 49.962

5.  Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies.

Authors:  Anna Kabanova; Laurent Perez; Daniele Lilleri; Jessica Marcandalli; Gloria Agatic; Simone Becattini; Silvia Preite; Dario Fuschillo; Elena Percivalle; Federica Sallusto; Giuseppe Gerna; Davide Corti; Antonio Lanzavecchia
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-01       Impact factor: 11.205

6.  Expression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system.

Authors:  Irmgard Hofmann; Yingxia Wen; Claudio Ciferri; Axel Schulze; Viola Fühner; Megan Leong; Andrea Gerber; Rachel Gerrein; Avishek Nandi; Anders E Lilja; Andrea Carfi; Holger Laux
Journal:  Biotechnol Bioeng       Date:  2015-07-31       Impact factor: 4.530

7.  HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.

Authors:  Joseph G Jardine; Takayuki Ota; Devin Sok; Matthias Pauthner; Daniel W Kulp; Oleksandr Kalyuzhniy; Patrick D Skog; Theresa C Thinnes; Deepika Bhullar; Bryan Briney; Sergey Menis; Meaghan Jones; Mike Kubitz; Skye Spencer; Yumiko Adachi; Dennis R Burton; William R Schief; David Nemazee
Journal:  Science       Date:  2015-06-18       Impact factor: 47.728

8.  Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

Authors:  Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham
Journal:  Science       Date:  2013-04-25       Impact factor: 47.728

9.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Authors:  Xiaodong Xiao; Weizao Chen; Yang Feng; Zhongyu Zhu; Ponraj Prabakaran; Yanping Wang; Mei-Yun Zhang; Nancy S Longo; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2009-09-11       Impact factor: 3.575

10.  Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.

Authors:  Bryan Briney; Devin Sok; Joseph G Jardine; Daniel W Kulp; Patrick Skog; Sergey Menis; Ronald Jacak; Oleksandr Kalyuzhniy; Natalia de Val; Fabian Sesterhenn; Khoa M Le; Alejandra Ramos; Meaghan Jones; Karen L Saye-Francisco; Tanya R Blane; Skye Spencer; Erik Georgeson; Xiaozhen Hu; Gabriel Ozorowski; Yumiko Adachi; Michael Kubitz; Anita Sarkar; Ian A Wilson; Andrew B Ward; David Nemazee; Dennis R Burton; William R Schief
Journal:  Cell       Date:  2016-09-08       Impact factor: 41.582

View more
  58 in total

Review 1.  Rationalizing Random Walks: Replicating Protective Antibody Trajectories.

Authors:  Jennifer L Remmel; Margaret E Ackerman
Journal:  Trends Immunol       Date:  2021-01-26       Impact factor: 16.687

2.  An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.

Authors:  Harekrushna Panda; Muzamil Ashraf Makhdoomi; Nitesh Mishra; Sanjeev Kumar; Haaris Ahsan Safdari; Himanshi Chawla; Heena Aggarwal; Elluri Seetharami Reddy; Rakesh Lodha; Sushil Kumar Kabra; Anmol Chandele; Somnath Dutta; Kalpana Luthra
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

3.  The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen.

Authors:  Colin Havenar-Daughton; Anita Sarkar; Daniel W Kulp; Laura Toy; Xiaozhen Hu; Isaiah Deresa; Oleksandr Kalyuzhniy; Kirti Kaushik; Amit A Upadhyay; Sergey Menis; Elise Landais; Liwei Cao; Jolene K Diedrich; Sonu Kumar; Torben Schiffner; Samantha M Reiss; Grégory Seumois; John R Yates; James C Paulson; Steven E Bosinger; Ian A Wilson; William R Schief; Shane Crotty
Journal:  Sci Transl Med       Date:  2018-07-04       Impact factor: 17.956

Review 4.  Toward rational vaccine engineering.

Authors:  Yashavantha L Vishweshwaraiah; Nikolay V Dokholyan
Journal:  Adv Drug Deliv Rev       Date:  2022-02-09       Impact factor: 15.470

Review 5.  An Update on "Reverse Vaccinology": The Pathway from Genomes and Epitope Predictions to Tailored, Recombinant Vaccines.

Authors:  Marcin Michalik; Bardya Djahanschiri; Jack C Leo; Dirk Linke
Journal:  Methods Mol Biol       Date:  2022

6.  Functional Optimization of Broadly Neutralizing HIV-1 Antibody 10E8 by Promotion of Membrane Interactions.

Authors:  Edurne Rujas; Daniel P Leaman; Sara Insausti; Lei Ortigosa-Pascual; Lei Zhang; Michael B Zwick; José L Nieva
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

Review 7.  The science and medicine of human immunology.

Authors:  Bali Pulendran; Mark M Davis
Journal:  Science       Date:  2020-09-25       Impact factor: 47.728

Review 8.  Broadly neutralizing antibodies in HIV-1 treatment and prevention.

Authors:  Rajesh Kumar; Huma Qureshi; Suprit Deshpande; Jayanta Bhattacharya
Journal:  Ther Adv Vaccines Immunother       Date:  2018-10-12

Review 9.  Multiple roles for HIV broadly neutralizing antibodies.

Authors:  Barton F Haynes; Dennis R Burton; John R Mascola
Journal:  Sci Transl Med       Date:  2019-10-30       Impact factor: 17.956

Review 10.  Antibodies against Plasmodium falciparum malaria at the molecular level.

Authors:  Jean-Philippe Julien; Hedda Wardemann
Journal:  Nat Rev Immunol       Date:  2019-08-28       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.